UCI MIND faculty member, Dr. Ruth Benca, discussed sleep, brain health, and Alzheimer’s disease at the October 2019 #MIHealthSummit in Washington, D.C., hosted by the Milken Institute. The session opens with a conversation with Maxine Waters, U.S. Representative of California, followed by a panel discussion among leading researchers and policymakers on the latest evidence regarding reducing risk for cognitive decline, including nutrition, exercise, sleep, socialization, and stress management. View the plenary session below.
Read More
Contributed by Bryce Mander, PhD A new landmark study from researchers in Boston was published in Science this month. This study linked human brain waves during deep sleep, called “slow waves,” with the pulsating flow of cerebrospinal fluid (CSF) through the brain. Fultz et al., 2019, NPR This study is important because it is the first to directly link sleeping brain waves with a mechanism thought to clear the brain of metabolic waste and toxins, called the “glymphatic system.” Prior studies in rodents indicate that the glymphatic system actively clears Alzheimer’s disease pathology, as well as other toxins and…
Read More
Contributed by David Sultzer, MD, Professor of Psychiatry & Human Behavior This past weekend, China’s regulatory agency conditionally approved sodium oligomannate for the treatment of mild to moderate Alzheimer’s disease. The approval was based on results from a 9-month treatment study of 818 people, and is the first approval globally of an Alzheimer’s drug in 16 years. Oligomannate (GV-971) is a plant-based complex sugar derived from ocean seaweed. It’s thought to adjust the microbiome in the GI tract, thereby tweaking amino acid levels in the body and reducing the toxic effects of brain inflammation that contribute to Alzheimer’s disease. Results from…
Read More
Facebook Live Series - ASK THE DOC: Alzheimer's Research Today! This monthly series features short talks and Q&A with experts from the University of California, Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND), 1 of 32 congressionally designated Alzheimer’s Disease Research Centers in the nation. Join UCI MIND on Facebook (@UCIrvineMIND) the first Friday of every month from 9:00-9:30 AM PST to learn about advances in research to improve Alzheimer’s disease diagnosis, treatment, and prevention. Episode 10: "Will I get Alzheimer's if I live long enough?" This month, we're joined by Maria Corrada, ScM, ScD, Professor of Neurology…
Read More
Tune in this Friday, November 1 @ 9AM for the next episode of our monthly Facebook LIVE series, "Will I get Alzheimer's if I live long enough?" This month, we're joined by Maria Corrada, ScM, ScD, Professor of Neurology and Epidemiology in the UCI School of Medicine. Dr. Corrada received a masters in Biostatistics and a doctorate in Epidemiology from Johns Hopkins University. She currently serves as co-principal investigator of The 90+ Study, a longitudinal study of aging and dementia in over 1,800 people aged 90 years and older, and Life After 90, a multiethnic cohort of people 90 and older in Northern California. Dr. Corrada's research focuses…
Read More
Contributed by Joshua Grill, PhD Yesterday morning, Biogen announced the company’s intention to file with the FDA for approval of Aducanumab, a monoclonal antibody that until recently had been in development as a potential disease-modifying therapy for Alzheimer’s disease. The news came as a shock to us, since two large Phase 3 clinical trials of Aducanumab had been halted for futility earlier in 2019. “Futility” is defined as an early indication that a trial is not likely to demonstrate a drug benefit. As a site for one of those trials, we – along with the research participants and the entire…
Read More
